HKD 5.8
(11.75%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 357.75 Million CNY | -86.72% |
2022 | 2.69 Billion CNY | 17.84% |
2021 | 2.28 Billion CNY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 319.44 Million CNY | -10.71% |
2024 Q2 | 319.44 Million CNY | 0.0% |
2023 FY | 357.75 Million CNY | -86.72% |
2023 Q2 | 172.43 Million CNY | 0.0% |
2023 Q1 | 172.43 Million CNY | -93.6% |
2023 Q3 | 357.75 Million CNY | 107.48% |
2023 Q4 | 357.75 Million CNY | 0.0% |
2022 Q3 | 2.69 Billion CNY | 0.0% |
2022 Q4 | 2.69 Billion CNY | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Uni-Bio Science Group Limited | 152.81 Million HKD | -134.107% |
CK Life Sciences Int'l., (Holdings) Inc. | 7.05 Billion HKD | 94.931% |